Brief: HLS Therapeutics Granted Priority Review Status From Health Canada For Vascepa
29/03/2019 19:20
March 29 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS GRANTED PRIORITY REVIEW STATUS FROM
HEALTH
CANADA FOR VASCEPA®
* HLS THERAPEUTICS INC - HLS NDS FILING TO OCCUR IN APRIL
2019
Source text for Eikon: ID:nCNWYkcNpa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease